Aethlon Medical Inc (AEMD)

Sep 22, 2026

Aethlon Medical and North Immunology have merged in an all-stock transaction, backed by an oversubscribed $180 million private placement, to advance NOR-101 for atopic dermatitis. The combined company, operating as North Immunology, Inc. (Nasdaq: NRTX), will fund NOR-101's development into phase 1 trials starting in early 2027, aiming to target both type 2 and non-type 2 inflammatory pathways. The merger is expected to close in Q1 2027, with preclinical data showing a favorable half-life for NOR-101.

Sep 21, 2026

Aethlon Medical Inc. (NASDAQ: AEMD) shares surged after the company announced an all-stock merger agreement with North Immunology Inc., a privately held biotech firm. The combined entity, to be named North Immunology, will trade on Nasdaq under the symbol NRTX and is backed by $180 million in private placement funding. This merger pivots Aethlon Medical into a biotechnology focus, aiming to advance North Immunology’s drug pipeline for inflammatory and immune diseases.

Sep 18, 2026

North Immunology is set to go public through an all-stock reverse merger with Aethlon Medical, Inc., accompanied by an oversubscribed $180 million private placement. This financing is intended to advance NOR-101, a bispecific antibody for atopic dermatitis, into clinical development with Phase Ia, Ib, and IIb studies planned for 2027. The combined company, which will operate as North Immunology, Inc. and trade under NRTX, expects the funding to support operations until the second half of 2028.

Sep 16, 2026

Aethlon Medical has updated its executive severance agreements to allow for one-time lump sum payments for severance and healthcare continuation following a change in control where existing shareholders retain 50% or less of voting power. This revision clarifies payment timing without altering the benefit amounts or eligibility criteria. The amendments apply to CEO and CFO James B. Frakes and Chief Medical Officer Steven P. LaRosa.